NurExone Biologic team members Lior Shaltiel, PhD, Lyora Aharonov and Inbar Paz Benayoun, Adv. at the MIXiii Health-Tech.IL in Jerusalem. It has been a pleasure to hear recent developments and network in the Life Science & health tech community! Read More…
Calgary, Alberta–(Newsfile Corp. – November 8, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by
NurExone Biologic team will be participating the MIXiii Health-Tech.IL conference as a leading Life-Science publicly traded company! Read More…
The healthcare sector is one of the industries that is rapidly recovering, and advances in drug research and development are yielding spectacular results. Canada is a global biotechnology leader, with the government assisting in the development of strong, competitive biomanufacturing and life sciences sector, making it a global investment opportunity
Prior to submission of a New Investigational Drug (IND) application, in September 2022, the Company submitted a request for an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting, which is an informal, non-binding meeting that is offered by the U.S. FDA to companies at an early stage
In Heath Tech World’s latest roundtable in a series of events we hear from leading experts in the SCI community. Read More
Exosomes, a key element of ExoTherapy, are derived from stem cells in bio-production processes. The Technion-developed process suggests that shear stress stimulation of stem cells during Three-Dimensional (3D) exosome production yields both increased secretion of exosomes and enhanced exosome potency. NurExone carried out a pilot study of the shear stress
Every year, between 250,000 and 500,000 people around the world sustain a spinal cord injury (SCI). Four industry figureheads came together last week to address this challenge in our exclusive roundtable. Catch up now on YouTube or read on for our highlights from the debate. Read More
Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability. With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI
The Company will be participating in the upcoming 2022 Bio-Europe Conference (“Bio-Europe”) in Leipzig, Germany, which commences on October 24th and ends on October 26th. Bio-Europe is regarded as one of Europe’s largest gathering of professionals in the biopharma industry. Over 4000 attendees and more than 2200 companies from around
